GLPG
Galapagos
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 6
consensus rating "Sell"
Revenue Plunges
Price Hits New Low
Price Hits 52-week low
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GLPG
Galapagos Nv
A developer of small molecule medicines for the treatment of inflammatory-related diseases
Pharmaceutical
06/30/1999
05/14/2015
NASDAQ Stock Exchange
704
12-31
Depository Receipts (Ordinary Shares)
Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
--
Galapagos Nv was incorporated in Belgium on June 30, 1999. The company is a global biotechnology company with operations in Europe and the United States that develops translational medicines for more years of life and quality of life. The company focuses on highly unmet medical needs, synergizing compelling science, technology and collaborative approaches to create a deep pipeline of potentially best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology.
Company Financials
EPS
GLPG has released its 2024 Q4 earnings. EPS was reported at -0.42, versus the expected -0.31, missing expectations. The chart below visualizes how GLPG has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GLPG has released its 2024 Q4 earnings report, with revenue of 78.14M, reflecting a YoY change of 17.86%, and net profit of 26.20M, showing a YoY change of -84.97%. The Sankey diagram below clearly presents GLPG’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
